Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer's disease

Annalena Venneri, Michael F. Shanks, Roger T. Staff, Simon J. Pestell, Katrina E. Forbes, Howard G. Gemmell, Alison D. Murray

Research output: Contribution to journalArticle

87 Citations (Scopus)

Abstract

Twenty seven patients with mild AD were enrolled in a prospective open label controlled study of rivastigmine. Assessments included a range of neuropsychiatric and behavioural measures and rCBF using HMPAO SPECT at baseline, three and six months. Significant enhancement of frontal, parietal and temporal brain blood flow with related psychometric improvement was observed in twelve of the treated patients. A pattern of reduced rCBF and cognitive performance was observed in four unresponsive and eleven untreated patients. The results suggest that alterations in the clinical and cognitive status of patients receiving a cholinesterase inhibitor are paralleled by changes in rCBF. Longitudinal assessment with repeated imaging offers a method of better understanding the effects of cholinesterase inhibition on the AD brain.

Original languageEnglish
Pages (from-to)83-87
Number of pages5
JournalNeuroReport
Volume13
Issue number1
Publication statusPublished - Jan 21 2002

Fingerprint

Rivastigmine
Cerebrovascular Circulation
Alzheimer Disease
Cholinesterase Inhibitors
Cholinesterases
Brain
Therapeutics
Single-Photon Emission-Computed Tomography
Psychometrics

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Venneri, A., Shanks, M. F., Staff, R. T., Pestell, S. J., Forbes, K. E., Gemmell, H. G., & Murray, A. D. (2002). Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer's disease. NeuroReport, 13(1), 83-87.

Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer's disease. / Venneri, Annalena; Shanks, Michael F.; Staff, Roger T.; Pestell, Simon J.; Forbes, Katrina E.; Gemmell, Howard G.; Murray, Alison D.

In: NeuroReport, Vol. 13, No. 1, 21.01.2002, p. 83-87.

Research output: Contribution to journalArticle

Venneri, A, Shanks, MF, Staff, RT, Pestell, SJ, Forbes, KE, Gemmell, HG & Murray, AD 2002, 'Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer's disease', NeuroReport, vol. 13, no. 1, pp. 83-87.
Venneri A, Shanks MF, Staff RT, Pestell SJ, Forbes KE, Gemmell HG et al. Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer's disease. NeuroReport. 2002 Jan 21;13(1):83-87.
Venneri, Annalena ; Shanks, Michael F. ; Staff, Roger T. ; Pestell, Simon J. ; Forbes, Katrina E. ; Gemmell, Howard G. ; Murray, Alison D. / Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer's disease. In: NeuroReport. 2002 ; Vol. 13, No. 1. pp. 83-87.
@article{00307b727e394eb2beee862154f2c0cf,
title = "Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer's disease",
abstract = "Twenty seven patients with mild AD were enrolled in a prospective open label controlled study of rivastigmine. Assessments included a range of neuropsychiatric and behavioural measures and rCBF using HMPAO SPECT at baseline, three and six months. Significant enhancement of frontal, parietal and temporal brain blood flow with related psychometric improvement was observed in twelve of the treated patients. A pattern of reduced rCBF and cognitive performance was observed in four unresponsive and eleven untreated patients. The results suggest that alterations in the clinical and cognitive status of patients receiving a cholinesterase inhibitor are paralleled by changes in rCBF. Longitudinal assessment with repeated imaging offers a method of better understanding the effects of cholinesterase inhibition on the AD brain.",
author = "Annalena Venneri and Shanks, {Michael F.} and Staff, {Roger T.} and Pestell, {Simon J.} and Forbes, {Katrina E.} and Gemmell, {Howard G.} and Murray, {Alison D.}",
year = "2002",
month = "1",
day = "21",
language = "English",
volume = "13",
pages = "83--87",
journal = "NeuroReport",
issn = "0959-4965",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer's disease

AU - Venneri, Annalena

AU - Shanks, Michael F.

AU - Staff, Roger T.

AU - Pestell, Simon J.

AU - Forbes, Katrina E.

AU - Gemmell, Howard G.

AU - Murray, Alison D.

PY - 2002/1/21

Y1 - 2002/1/21

N2 - Twenty seven patients with mild AD were enrolled in a prospective open label controlled study of rivastigmine. Assessments included a range of neuropsychiatric and behavioural measures and rCBF using HMPAO SPECT at baseline, three and six months. Significant enhancement of frontal, parietal and temporal brain blood flow with related psychometric improvement was observed in twelve of the treated patients. A pattern of reduced rCBF and cognitive performance was observed in four unresponsive and eleven untreated patients. The results suggest that alterations in the clinical and cognitive status of patients receiving a cholinesterase inhibitor are paralleled by changes in rCBF. Longitudinal assessment with repeated imaging offers a method of better understanding the effects of cholinesterase inhibition on the AD brain.

AB - Twenty seven patients with mild AD were enrolled in a prospective open label controlled study of rivastigmine. Assessments included a range of neuropsychiatric and behavioural measures and rCBF using HMPAO SPECT at baseline, three and six months. Significant enhancement of frontal, parietal and temporal brain blood flow with related psychometric improvement was observed in twelve of the treated patients. A pattern of reduced rCBF and cognitive performance was observed in four unresponsive and eleven untreated patients. The results suggest that alterations in the clinical and cognitive status of patients receiving a cholinesterase inhibitor are paralleled by changes in rCBF. Longitudinal assessment with repeated imaging offers a method of better understanding the effects of cholinesterase inhibition on the AD brain.

UR - http://www.scopus.com/inward/record.url?scp=0037148175&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037148175&partnerID=8YFLogxK

M3 - Article

VL - 13

SP - 83

EP - 87

JO - NeuroReport

JF - NeuroReport

SN - 0959-4965

IS - 1

ER -